FDA expands use of Zoryve to include young children with plaque psoriasis

FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis

Expanded Pediatric Use for Roflumilast Under FDA Review

If approved, topical roflumilast 0.05% will be approved for treating atopic dermatitis down to age 3 months. Medscape Medical News

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

Conditions : Seborrheic Dermatitis Interventions : Drug: Roflumilast Foam 0.3%; Drug: Vehicle foam Sponsors : Hangzhou Zhongmei Huadong Phar

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

Conditions : Hidradenitis Suppurativa (HS) Interventions : Drug: Roflumilast 0.3% topical foam Sponsors : Harrison Dermatology Not yet recru

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Conditions : Moderate-to-Severe Atopic Dermatitis Interventions : Drug: Rezpegaldesleukin; Drug: Placebo Sponsors : Nektar Therapeutics Recr

FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years

Federal health regulators have signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years. The announcement